Promising CLL combo trial halted early — only 5 patients enrolled
NCT ID NCT03514017
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This small Phase 2 trial tested two drugs — ibrutinib and pembrolizumab — in people with untreated high-risk chronic lymphocytic leukemia (CLL). The goal was to see if the combination could improve the body's immune function and shrink or control the cancer. However, the study was terminated early after enrolling only 5 participants, so we have very little information about how well it worked or what side effects occurred.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ibrutinib (Imbruvica) and pembrolizumab (Keytruda)
What this could lead to
If it worked, this combination might improve immune function and control high-risk CLL better than current treatments.
What could go wrong
The trial was terminated early with only 5 participants, so results are very limited. It is unclear if the combination is safe or effective, and it may not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States